Key facts
- This page summarizes Fred Aslan's Form 4 filing for Artiva Biotherapeutics, Inc. (ARTV).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 15 Sep 2026, 16:44.
Fred Aslan - 15 Sep 2026 Form 4 Insider Report for Artiva Biotherapeutics, Inc. (ARTV)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- ARTV
- Reported as of
- 15 Sep 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 15 Sep 2026, 16:44:04 UTC
- Prior SEC filing
- 14 Sep 2026
- Next SEC filing
- 06 Oct 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jennifer Bush, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Fred Aslan filed Form 4 for Artiva Biotherapeutics, Inc. (ARTV) on 15 Sep 2026.
Change
- Previous filing in this sequence was filed on 14 Sep 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001909362
Primary reporting owner
Aslan Fred
- Relationship
- Chief Executive Officer, Director
- Address
- C/O ARTIVA BIOTHERAPEUTICS, INC., 5505 MOREHOUSE DRIVE, SUITE 100, SAN DIEGO
- Signature
- /s/ Jennifer Bush, Attorney-in-Fact
- Signature date
- 15 Sep 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ARTV
transaction
Common Stock
Award
- Transaction value
- Shares
- +110,000
- Change %
- +7.4%
- Price
- $0.000000*
- Shares after
- 1,604,765
- Date
- 15 Sep 2026
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ARTV
transaction
Derivative
Employee Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +315,000
- Change %
- Price
- $0.000000*
- Shares after
- 315,000
- Date
- 15 Sep 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 315,000
- Exercise price
- $8.91
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan.
Footnote F2
Beginning on September 8, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four-year period.